Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy

NCT00106522 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT00106522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00106522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind Study of Safety and Reduction in Signs and Symptoms During Treatment With Tocilizumab Versus Placebo, in Combination With Methotrexate, in Patients With Moderate to Severe Active Rheumatoid Arthritis and Inadequate Response to Anti-TNF Therapy
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2005
Completion date
November 30, 2007
Enrollment
499 (actual)
Sites
168

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis